drugset / Trial / NCT04635735
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Phase 1/2
Terminated
3 enrolled
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.
Timeline
- Start
- 2020-01-12
- Primary completion
- 2023-02-02
- Completion
- 2023-02-02
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |